The Associations of Advanced Glycation End Products and Its Soluble Receptor with Pancreatic Cancer Risk: A Case-Control Study within the Prospective EPIC Cohort

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3153137 25 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
The Associations of Advanced Glycation End Products and Its Soluble
Receptor with Pancreatic Cancer Risk: A Case-Control Study within the
Prospective EPIC Cohort
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Advanced glycation end products (AGE) and their receptors
(RAGE) have been implicated in cancer development through their
proinflammatory capabilities. However, prospective data on their
association with cancer of specific sites, including pancreatic cancer,
are limited.
Methods: Prediagnostic blood levels of the AGE product
Ne-(carboxymethyl) lysine (CML) and the endogenous secreted receptor for
AGE (esRAGE) were measured using ELISA in 454 patients with exocrine
pancreatic cancer and individually matched controls within the European
Prospective Investigation into Cancer and Nutrition (EPIC). Pancreatic
cancer risk was estimated by calculating ORs with corresponding 95%
confidence intervals (CI).
Results: Elevated CML levels tended to be associated with a reduction in
pancreatic cancer risk [OR = 0.57 (95% CI, 0.32-1.01) comparing
highest with lowest quintile), whereas no association was observed for
esRAGE (OR = 0.98; 95% CI, 0.62-1.54). Adjustments for body mass index
and smoking attenuated the inverse associations of CML with pancreatic
cancer risk (OR = 0.78; 95% CI, 0.41-1.49). There was an inverse
association between esRAGE and risk of pancreatic cancer for cases that
were diagnosed within the first 2 years of follow-up [OR = 0.46 (95%
CI, 0.22-0.96) for a doubling in concentration], whereas there was no
association among those with a longer follow-up (OR = 1.11; 95% CI,
0.88-1.39; P-interaction = 0.002).
Conclusions and Impact: Our results do not provide evidence for an
association of higher CML or lower esRAGE levels with risk of pancreatic
cancer. The role of AGE/RAGE in pancreatic cancer would benefit from
further investigations. Cancer Epidemiol Biomarkers Prev; 21(4); 619-28.
(C) 2012 AACR.
Έτος δημοσίευσης:
2012
Συγγραφείς:
Grote, Verena A.
Nieters, Alexandra
Kaaks, Rudolf and
Tjonneland, Anne
Roswall, Nina
Overvad, Kim
Nielsen, Michael
R. Skjelbo
Clavel-Chapelon, Francoise
Boutron-Ruault, Marie
Christine
Racine, Antoine
Teucher, Birgit
Lukanova,
Annekatrin
Boeing, Heiner
Drogan, Dagmar
Trichopoulou,
Antonia
Trichopoulos, Dimitrios
Lagiou, Pagona
Palli,
Domenico
Sieri, Sabina
Tumino, Rosario
Vineis, Paolo and
Mattiello, Amalia
Argueelles Suarez, Marcial Vicente
Duell, Eric
J.
Sanchez, Maria-Jose
Dorronsoro, Miren
Huerta Castano,
Jose Maria
Barricarte, Aurelio
Jeurnink, Suzanne M.
Peeters,
Petra H. M.
Sund, Malin
Ye, Weimin
Regner, Sara and
Lindkvist, Bjorn
Khaw, Kay-Tee
Wareham, Nick
Allen, Naomi E.
and Crowe, Francesca L.
Fedirko, Veronika
Jenab, Mazda and
Romaguera, Dora
Siddiq, Afshan
Bueno-de-Mesquita, H. Bas and
Rohrmann, Sabine
Περιοδικό:
Cancer Epidemiology, Biomarkers & Prevention
Εκδότης:
AMER ASSOC CANCER RESEARCH
Τόμος:
21
Αριθμός / τεύχος:
4
Σελίδες:
619-628
Επίσημο URL (Εκδότης):
DOI:
10.1158/1055-9965.EPI-11-1139
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.